Patient demographics, sites of disease, prior therapies, cell treatments received, and clinical outcome*
Patient . | Age, y/sex . | Sites of metastases . | Prior therapies . | No. cells received, × 1010 . | Ag reactivity . | No. IL-2 doses . | Tumor response (duration, mo) . | Autoimmunity . |
|---|---|---|---|---|---|---|---|---|
| 9 | 57/M | Cutaneous, subcutaneous | S, IT, IFN-α, HD IL-2 | 9.6 | MART-1 | 10 | PR (11) | Vitiligo |
| 10 | 55/M | LN, cutaneous, subcutaneous | S, IT, C, HD IL-2 | 10.7 | MART-1† | 12 | PR (14) | Uveitis |
| 20 | 30/M | LN, lung, adrenal, subcutaneous | S, IT, HD IL-2 | 5.8 | MART-1 | 9 | Mixed | Vitiligo, Uveitis |
| 21 | 48/F | Subcutaneous, lung | S, C, IT, HD IL-2 | 2.8 | Autol Vβ22 | 6 | PR (15+) | None |
| 23 | 45/M | LN, parotid, subcutaneous | S, C, IFN-α, R, IT, HD IL-2 | 1.8 | MART-1 | 13 | Mixed | None |
| 28 | 54/M | LN, brain | S, IT, HD IL-2 | 10.4 | MART-1 | 5 | PR (4) | Uveitis |
Patient . | Age, y/sex . | Sites of metastases . | Prior therapies . | No. cells received, × 1010 . | Ag reactivity . | No. IL-2 doses . | Tumor response (duration, mo) . | Autoimmunity . |
|---|---|---|---|---|---|---|---|---|
| 9 | 57/M | Cutaneous, subcutaneous | S, IT, IFN-α, HD IL-2 | 9.6 | MART-1 | 10 | PR (11) | Vitiligo |
| 10 | 55/M | LN, cutaneous, subcutaneous | S, IT, C, HD IL-2 | 10.7 | MART-1† | 12 | PR (14) | Uveitis |
| 20 | 30/M | LN, lung, adrenal, subcutaneous | S, IT, HD IL-2 | 5.8 | MART-1 | 9 | Mixed | Vitiligo, Uveitis |
| 21 | 48/F | Subcutaneous, lung | S, C, IT, HD IL-2 | 2.8 | Autol Vβ22 | 6 | PR (15+) | None |
| 23 | 45/M | LN, parotid, subcutaneous | S, C, IFN-α, R, IT, HD IL-2 | 1.8 | MART-1 | 13 | Mixed | None |
| 28 | 54/M | LN, brain | S, IT, HD IL-2 | 10.4 | MART-1 | 5 | PR (4) | Uveitis |
LN indicates lymph node; S, surgery; IT, experimental immunotherapy; IFN-α, interferon alpha; HD IL-2, high-dose intravenous interleukin-2; PR, objective partial response, 50% or more decrease in the sum of the products of perpendicular diameters of all measurable lesions for one month or more without increases in any lesion or appearance of new lesions; C, chemotherapy; mixed, mixed response, shrinkage in some lesions but an increase in others; and R, radiation therapy.
Patients 20 and 23 had each received a prior lymphodepleting chemotherapy followed by cell transfer and IL-2. The lymphocytes analyzed in this report (course 2) differed substantially from those administered during their first treatment, and no persistent cell population for course 1 was observed prior to the initiation of course 2 (data not shown).
TIL from patient 10 recognized native MART-1:(27-35) peptide but not modified (27L) peptide.